Literature DB >> 26921119

Structure, Aggregation, and Activity of a Covalent Insulin Dimer Formed During Storage of Neutral Formulation of Human Insulin.

Christian Fogt Hjorth1, Mathias Norrman2, Per-Olof Wahlund2, Andrew J Benie2, Bent O Petersen2, Christian M Jessen3, Thomas Å Pedersen4, Kirsten Vestergaard4, Dorte B Steensgaard2, Jan Skov Pedersen5, Helle Naver2, František Hubálek2, Christian Poulsen2, Daniel Otzen6.   

Abstract

A specific covalently linked dimeric species of insulin high molecular weight products (HMWPs), formed during prolonged incubation of a neutral pharmaceutical formulation of human insulin, were characterized in terms of tertiary structure, self-association, biological activity, and fibrillation properties. The dimer was formed by a covalent link between A21Asn and B29Lys. It was analyzed using static and dynamic light scattering and small-angle X-ray scattering to evaluate its self-association behavior. The tertiary structure was obtained using nuclear magnetic resonance and X-ray crystallography. The biological activity of HMWP was determined using 2 in vitro assays, and its influence on fibrillation was investigated using Thioflavin T assays. The dimer's tertiary structure was nearly identical to that of the noncovalent insulin dimer, and it was able to form hexamers in the presence of zinc. The dimer exhibited reduced propensity for self-association in the absence of zinc but significantly postponed the onset of fibrillation in insulin formulations. Consistent with its dimeric state, the tested species of HMWP showed little to no biological activity in the used assays. This study is the first detailed characterization of a specific type of human insulin HMWP formed during storage of a marketed pharmaceutical formulation. These results indicate that this specific type of HMWP is unlikely to antagonize the physical stability of the formulation, as HMWP retained a tertiary structure similar to the noncovalent dimer and participated in hexamer assembly in the presence of zinc. In addition, increasing amounts of HMWP reduce the rate of insulin fibrillation.
Copyright © 2016 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  SAXS; ThT assay; X-ray crystallography; covalent insulin dimer; fibrillation; high molecular weight products

Mesh:

Substances:

Year:  2016        PMID: 26921119     DOI: 10.1016/j.xphs.2016.01.003

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  6 in total

Review 1.  Insulin Formulation Characterization-the Thioflavin T Assays.

Authors:  Morten Schlein
Journal:  AAPS J       Date:  2016-12-20       Impact factor: 4.009

2.  Comparison of NMR and Dynamic Light Scattering for Measuring Diffusion Coefficients of Formulated Insulin: Implications for Particle Size Distribution Measurements in Drug Products.

Authors:  Sharadrao M Patil; David A Keire; Kang Chen
Journal:  AAPS J       Date:  2017-08-08       Impact factor: 4.009

3.  Direct observation of protein structural transitions through entire amyloid aggregation processes in water using 2D-IR spectroscopy.

Authors:  So Yeon Chun; Myung Kook Son; Chae Ri Park; Chaiho Lim; Hugh I Kim; Kyungwon Kwak; Minhaeng Cho
Journal:  Chem Sci       Date:  2022-03-18       Impact factor: 9.969

4.  Distribution of insulin in trigeminal nerve and brain after intranasal administration.

Authors:  Jeffrey J Lochhead; Kathryn L Kellohen; Patrick T Ronaldson; Thomas P Davis
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379

5.  Insulin Complexation with Cyclodextrins-A Molecular Modeling Approach.

Authors:  Pálma Bucur; Ibolya Fülöp; Emese Sipos
Journal:  Molecules       Date:  2022-01-11       Impact factor: 4.411

6.  Rational Development of Stable PYY3-36 Peptide Y2 Receptor Agonists.

Authors:  Christian Poulsen; Marie Østergaard Pedersen; Per-Olof Wahlund; Annika Sjölander; Jens Kaalby Thomsen; Kilian W Conde-Frieboes; Johan F Paulsson; Birgitte S Wulff; Søren Østergaard
Journal:  Pharm Res       Date:  2021-07-16       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.